Compare Gilead Sciences, Inc. (GILD) vs Visa Inc (V) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Visa Inc — how do they compare? Gilead Sciences, Inc. trades at $135.54 (market cap $163.51B), while Visa Inc trades at $362.13 (market cap $675.39B). The key difference: Visa Inc is far larger — about 4.1× Gilead Sciences, Inc.'s market cap, and Gilead Sciences, Inc. pays the higher dividend (2.49%). Which is the better fit depends on your goals.
| GILD | V | |
|---|---|---|
Market Cap | $163.51B | $675.39B |
Sector | Health | Financials |
52-Week High | $155.80 | $362.13 |
52-Week Low | $108.22 | $295.52 |
Enterprise Value | $178.05B | $685.98B |
Dividend Yield | 2.49% | 0.75% |
Volume | — | 10,431,336 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Visa (V) trades at $361.72, up 1.6% on the day, with a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $3.31 exceeding the $3.10 expectation. Revenue grew to $40 billion in 2025, and the company maintains high profitability with a net income margin of 51.68%. Recent news highlights Visa's push into AI-driven commerce and stablecoin partnerships, positioning it for future growth.
The outlook for Visa remains positive, supported by robust earnings, a dominant market position, and strategic initiatives in digital payments. Key risks include competitive pressures from fintech and regulatory scrutiny. With 85% of analysts rating it a Buy and a consensus price target of $396.70, the stock offers potential upside, but investors should monitor execution on AI integration and payment industry shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Visa Inc
Visa Inc. operates a retail electronic payments network and manages global financial services. The Company also offers global commerce through the transfer of value and information among financial institutions, merchants, consumers, businesses, and government entities.
Read more on V →
